Publications by authors named "E Solligard"
Background: Early diagnosis and antibiotic therapy in patients with sepsis reduce morbidity and mortality, thus pre-hospital management is likely to affect patient outcomes. Pre-hospital administration may increase the risk of unnecessary use of broad-spectrum antibiotics, but identification of an infectious focus enables more targeted antibiotic therapy. The aim of this study was to investigate how paramedics, with or without the assistance of general practitioners, can administer empiric intravenous antibiotic treatment against sepsis in a timely manner.
View Article and Find Full Text PDFBackground: Our goal was to identify genetic and modifiable risk factors for upper urinary tract infections (UTIs).
Methods: We used data from UK Biobank, the Trøndelag Health Study, and the Michigan Genomics Initiative to conduct genome-wide association studies and sex-stratified analyses on upper UTI. Mendelian randomization (MR) analyses were conducted to examine potential causal relationships between cardiometabolic risk factors and upper UTIs.
Purpose: Bloodstream infections (BSI) and sepsis are important causes of hospitalization, loss of health, and death globally. Targetable risk factors need to be identified to improve prevention and treatment. In this study, we aimed to evaluate the association of chronic kidney disease (CKD) and risk of and mortality from BSI and sepsis in the general population during a 22-year period.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the potential benefits of inhibiting PCSK9, a protein, to improve the clearance of bacteria from the bloodstream and enhance outcomes in sepsis treatment.
- Researchers used genetic studies, a clinical trial analysis, and experimental animal models to explore the relationship between PCSK9 inhibition and sepsis mortality.
- Results showed a correlation in human cohorts between PCSK9 loss-of-function variants and lower sepsis mortality rates, while the clinical trial indicated low frequency of sepsis events among participants treated with alirocumab, a PCSK9 inhibitor.